Genocea Biosciences Inc IPO év
Mi az Genocea Biosciences Inc IPO év?
A IPO év az Genocea Biosciences Inc - 2014
Mi a IPO év meghatározása?
A kezdeti nyilvános ajánlattétel olyan nyilvános ajánlattétel, amelyben a társaság részvényeit általában olyan intézményi befektetőknek adják el, akik viszont értékpapírcserében először értékesítik a nagyközönségnek.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO év a Health Care szektor a NASDAQ-on cégekben a Genocea Biosciences Inc -hoz képest
Mit csinál Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
ipo év -hoz hasonló cégek Genocea Biosciences Inc
- Australian REIT Income Fund nak IPO év 2013 van
- Brookfield Asset Management PRF SH CL A SE37 nak IPO év 2013 van
- Modern Meat nak IPO év 2013 van
- Blue Capital Reinsurance Ltd nak IPO év 2013 van
- Siyata Mobile nak IPO év 2013 van
- Mirati Therapeutics Inc nak IPO év 2013 van
- Genocea Biosciences Inc nak IPO év 2014 van
- Glaukos nak IPO év 2015 van
- UBS ETFs Public - MSCI ACWI SF UCITS ETF nak IPO év 2015 van
- Acasta Enterprises nak IPO év 2015 van
- Faron Pharmaceuticals Oy nak IPO év 2015 van
- GreenPower Motor Co nak IPO év 2015 van
- Sunrun Inc nak IPO év 2015 van